Diabetic kidney disease — MCCQE Part 1 MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Add an SGLT2 inhibitor for kidney and cardiovascular protection
Diabetes Canada guidance supports SGLT2 inhibitors in type 2 diabetes with chronic kidney disease for kidney and cardiovascular benefit when eGFR permits. Persistent albuminuria is not a reason to stop a tolerated ACE inhibitor. Glyburide can cause hypoglycaemia and is not kidney-protective. Waiting until advanced CKD misses the prevention window.
Reference: Diabetes Canada 2024 pharmacologic update